



**Eisai Co., Ltd.**

**4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 , Japan**

**Phone: 03- 3817-5120**

**Fax: 03- 3811-3077**

*Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.*

---

**FOR IMMEDIATE RELEASE**

No. 08-22

April 16, 2008

Eisai Co., Ltd.

**European Regulatory Agency Grants Orphan Status  
to Morphotek<sup>®</sup>'s FARLETUZUMAB (MORAb-003) and MORAb-009**

*Upon marketing authorization orphan status would provide for ten years of market  
exclusivity in the European Union for both investigational treatments*

Morphotek<sup>®</sup>, Inc.(Headquarters: Pennsylvania, President and CEO: Nicholas C. Nicolaides), a U.S. subsidiary of Eisai Co., Ltd (Headquarters: Tokyo, President and CEO: Haruo Naito), announced today that the European Commission has granted orphan drug status to the monoclonal antibodies -- farletuzumab (also known as MORAb-003) for the treatment of ovarian cancer and MORAb-009 for the treatment of pancreatic cancer.

